ArticleDiabetes care2013

Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013.

Guntram Schernthaner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.